Emerging Treatment Options for Psoriatic Arthritis

Psoriatic arthritis (PsA) is a chronic, heterogeneous inflammatory disease that may cause joint destruction and functional disability. Treatment must be established early, using disease-modifying antirheumatic drugs to prevent structural damage and impaired function. The number of therapeutic options for PsA has increased over the last 20 years. However, there are still patients who do not achieve the therapeutic goals. For this reason, it is necessary to go further in the study of the pathogenesis of PsA to develop new treatment targets. New molecules are being introduced, mostly from psoriasis, such as IL23 and IL17 inhibitors, and from rheumatoid arthritis, such as new JAK inhibitors. The objective of this article was to review the ongoing and recently reported clinical trials of upcoming drugs for the treatment of PsA.